News

Evaluation of the Deeplex® Myc-TB Assay: A major advance in mycobacterial diagnosis and drug resistance detection The rapid and accurate diagnosis of mycobacterial infections remains a major public health challenge. Distinguishing bacteria belonging to the Mycobacterium tuberculosis complex (MTBC), which causes tuberculosis, from nontuberculous mycobacteria (NTM) is essential for guiding

Advancing tuberculosis detection: From patient stories to innovative NGS solutions Tuberculosis remains one of the leading infectious diseases worldwide, requiring continuous innovation in detection and treatment. Behind the global fight against TB are both powerful human stories and groundbreaking scientific advances that are transforming patient care. A tuberculosis survivor’s story

Helicobacter pylori: a persistent carcinogenic threat amid a growing gastric cancer burden Helicobacter pylori, classified as a Group 1 carcinogen¹ by the World Health Organization, is the leading cause of gastric cancer, a disease associated with high morbidity and a frequently poor prognosis. Yet this chronic infection is largely preventable

Deeplex® Myc-TB: Cost-saving & cost-effective TB resistance detection A recent study conducted in South Africa demonstrates the clinical value and cost-effectiveness of targeted next-generation sequencing for tuberculosis drug resistance testing, using Deeplex Myc-TB. It demonstrates that this approach improves the speed and accuracy of diagnosis, optimizes treatment management, reduces infectiousness

New evidence supports Deeplex® Myc-TB as the reference method for enhanced drug-resistant TB detection Antibiotic resistance: WHO issues warning The World Health Organization (WHO) has published a new alarming report on the global rise of antibiotic resistance. According to its estimates, one-sixth of common bacterial infections worldwide were resistant to